Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;87(2):788-799.
doi: 10.1007/s12020-024-04082-x. Epub 2024 Oct 25.

Co-expression of multiple transcription factors is associated with clinical features and endocrine prognosis in growth hormone-secreting pituitary adenomas

Yu Zhang #  1 , Hanlu Tang #  1 , Shiwei Li #  1 , Zhixu Bie  1 , Xin Ma  1 , Hongyu Wu  1 , Gemingtian Liu  1 , Xingchao Wang  1 , Pinan Liu  2   3 , Zhijun Yang  4
Affiliations

Co-expression of multiple transcription factors is associated with clinical features and endocrine prognosis in growth hormone-secreting pituitary adenomas

Yu Zhang et al. Endocrine. 2025 Feb.

Abstract

Background: The types of growth hormone-secreting pituitary adenomas are diverse, we have found that there are significant differences in clinical features and prognosis between PIT-1 single-cell spectrum growth hormone adenomas and growth hormone phenotypic polyhormonal adenomas.

Methods: This study examined a cohort of 193 patients with growth hormone-secreting pituitary adenoma (GHPA), stratifying them into two groups: PIT-1 single transcription factor positive growth hormone adenoma (STF-GHPA) and Multiple transcription factor-positive growth hormone-secreting adenomas (MTF-GHPA). The objective was to compare these two groups' clinical characteristics. Within the MTF-GHPA group, we further subtyped them based on transcription factors to evaluate potential variations in clinical manifestations. Logistic regression analyses were employed to develop a risk factor model for investigating factors influencing hormone remission.

Results: There were no statistically significant differences in terms of age, gender, serum GH, and IGF-1 levels between patients diagnosed with MTF-GHPA and STF-GHPA. However, patients with MTF-GHPA exhibited a higher proportion of hypopituitarism compared to those with STF-GHPA. Furthermore, MTF-GHPA were characterized by smaller tumor size and less invasiveness, as indicated by lower Knosp classes. However, patients with MTF-GHPA have a lower rate of hormonal remission (30.8%) and more postoperative complications (31.0%), which means that STF-GHPA (hormonal remission:71.6%; postoperative complications:13.4%) has a better endocrine outcome than MTF-GHPA patients. Between the PIT-1 + SF-1+ and PIT-1 + TPIT+ subtypes within MTF-GHPA, significant differences were also observed in tumor size, endocrine outcomes, and postoperative complications. Risk factors influencing hormonal remission for GHPA included preoperative GH level, primary/recurrent, extent of resection, and transcription factor expression.

Conclusion: Co-expression of multiple transcription factors is an important factor associated with clinical behavior and endocrine outcomes in patients with GHPA.

Keywords: Endocrine; GHPA; Pituitary tumors; Prognosis; Transcription factor.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards. Conflict of interest: The authors declare no competing interests. Ethical approval: This study was approved by the ethics committee of Beijing Tiantan Hospital, Capital Medical University (KY2022-209-02). Informed consent was obtained from all individual participants included in the study. This study was performed in line with the principles of the Declaration of Helsinki.

Similar articles

See all similar articles

Cited by

References

    1. M.E. Molitch, Diagnosis and treatment of pituitary adenomas: A review. JAMA 317, 516–524 (2017) - DOI - PubMed
    1. M. Fleseriu, F. Langlois, D.S.T. Lim et al. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diab. Endocrinol. 10, 804–826 (2022) - DOI
    1. M. Buchfelder, S.-M. Schlaffer, Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas. Rev. Endocr. Metab. Disord. 21, 253–261 (2020) - DOI - PubMed - PMC
    1. F. Roelfsema, N.R. Biermasz, A.M. Pereira, Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1), 71–83 (2012) - DOI - PubMed
    1. H. Lasolle, M.H. Elsensohn, A. Wierinckx et al. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis. Acta Neuropathol. Commun. 8, 1–14 (2020) - DOI

MeSH terms

LinkOut - more resources